Aurobindo Pharma gained 1.01% to Rs 175.25 at 12:24 IST on BSE, having recovered from the session's low of Rs 167.05, on getting nod from the Canadian regulatory authority to sell its gabapentin capsules in multiple strengths in that country.
The drug is the generic version of Pfizer's Neurotin capusules used for treating seizures in patients diagnosed with epilepsy.
The company announced the approval during trading hours today, 6 January 2009.
The stock hit a high of Rs 175.85 and a low of Rs 167.05 so far during the day. The stock hit a 52-week high of Rs 533 on 8 January 2008 and a 52-week low of Rs 101.60 on 6 November 2008.
The company's current equity is Rs 26.88 crore. Face value per share is Rs 5.
Aurobindo Pharma had on 31 December 2008 received final approval from US Food & Drug Administration (US FDA) to manufacture and market Stavudine Capsules in multiple strengths and Stavudine solution in 1 miligram strength. The drug is the generic version of Bristol Myers Squibb's Zerit Capsules and solution. Stavudine can be used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV)-1 infection.
Aurobindo Pharma had on 24 December 2008 received Canadian regulatory approval to sell terbinafine hydrochloride tablets in multiple strengths.
Aurobindo Pharma reported a net loss of Rs 38.50 crore in Q2 September 2008 as compared to net profit of Rs 100.92 crore in Q2 September 2007. Net sales rose 2.1% to Rs 624.68 crore in Q2 September 2008 over Q2 September 2007.
Aurobindo Pharma is engaged in developing, manufacturing and marketing active pharmaceutical ingredients, intermediates and generic formulations.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment